387M-1

Olig2 (211F1.1) Mouse Monoclonal Antibody

• NACRES: NA.41
• UNSPSC Code: 12352203
• Conjugate: unconjugated
• Clone: 211F1.1, monoclonal
• Application: IHC (p)
• Citations: 2

Propiedades

• Quality Segment: 100, 500
• biological source: mouse
• conjugate: unconjugated
• antibody form: culture supernatant
• antibody product type: primary antibodies
• clone: 211F1.1, monoclonal
• description: For In Vitro Diagnostic Use in Select Regions (See Chart)
• form: buffered aqueous solution
• species reactivity: human
• packaging: vial of 0.1 mL concentrate (387M-14), vial of 0.5 mL concentrate (387M-15), bottle of 1.0 mL predilute (387M-17), vial of 1.0 mL concentrate (387M-16), bottle of 7.0 mL predilute (387M-18)
• manufacturer/tradename: Cell Marque^®
• technique(s): immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
• isotype: IgG2aκ
• control: astrocytoma
• shipped in: wet ice
• storage temp.: 2-8°C
• visualization: nuclear
• Gene Information: human ... OLIG2(10215)

Descripción

General description

Olig2, a basic helix–loop–helix transcription factor, is involved in oligodendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas[1][2]. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuroepithelial tumors, ependymomas, subependymomas, medulloblastomas, and nonneuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid/rhabdoid tumor, and haemangioblastomas[1][2]. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue (gliosis). In order to characterize cellular subtypes that constitute astrocytomas, oligoastrocytomas and oligodendrogliomas, double labeling of Olig2 and GFAP has been performed which identified two phenotypically distinct tumor populations. The first is Olig2+/GFAP– which has an oligodendroglial morphology, corresponding to pure oligodendrogliomas that contain only oligodendroglial cells; the second is Olig2–/GFAP+ which has an astrocytic phenotype, including not only oligoastrocytomas, but also WHO astrocytomas. Depending on proportion and spatial clustering of the two phenotypically distinct tumor populations, the tumor (Olig2-/GFAP+) is classified either as an astrocytoma when both populations are intermingled with a dominance of GFAP+ cells or oligoastrocytoma when there is some degree of spatial clustering of the GFAP+ cells.

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Analysis Note

IVD

IVD

IVD

NA

Other Notes

For Technical Service please contact: 800-665-7284 or email: [email protected]

Olig2 Positive Control Slides, Product No. 387S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany